NEW YORK (GenomeWeb News) – Fluidigm has decided to the pull the plug on its proposed initial public offering “due to the historic instability in the market,” the firm said today.
The South San Francisco-based company had expected to offer 5.3 million shares of common stock at a price of between $14 and $16 per share. It had expected to raise net proceeds of between $70.8 million and $81.9 million from the offering, which was to fund sales and marketing initiatives, R&D activities, and facilities and manufacturing expansion.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.